Immunic, Inc recently received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application 16/644581, entitled, “IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation.”
The company also received notice of allowance of patent application EP18762111.5 in Europe, and notice of grant of patent application 2018330633 in Australia. All three patents cover composition-of-matter of IMU-935 and related formulations, and are expected to provide protection into at least 2038, without accounting for potential Patent Term Extension (PTE) in the US or Supplementary Protection Certificates (SPC) in Europe, respectively.
“We believe IMU-935 is a highly potent and selective oral inhibitor of IL-17, which, so far, has shown a remarkably differentiated safety and tolerability profile. Allowance of composition-of-matter patents for this molecule in the US, Europe and Australia, each with significant lifespan, is incredibly important as we continue to advance IMU-935 through the clinic,” stated Daniel Vitt, PhD, Chief Executive Officer and President, Immunic.
He further said, “This is especially true on the heels of our recently announced positive results from the single and multiple ascending dose parts of the phase-I clinical trial of IMU-935, and the ongoing part C in moderate-to-severe psoriasis patients. Additionally, our ongoing phase-I clinical trial of IMU-935 in patients with metastatic castration-resistant prostate cancer continues to enroll patients and we look forward to receive initial clinical data from this indication as well.”